Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
Novo Nordisk (NYSE:NVO) has entered a partnership with OpenAI to apply artificial intelligence across drug discovery, manufacturing, and supply chain operations.
The company is preparing a global rollout of the oral Wegovy weight loss pill after its US launch.
Recent trial data for semaglutide and pipeline drugs such as Amycretin and CagriSema indicate further progress in obesity and metabolic disease treatments.
Novo Nordisk is drawing fresh attention as it pairs an AI push with a growing obesity and metabolic disease franchise. The stock trades at $44.39, with the share price down 32.7% over the past year but up 21.5% over five years. This mixed performance comes amid strong interest in weight management therapies and rising competition from Eli Lilly.
For investors following NYSE:NVO, the OpenAI partnership and the planned global Wegovy pill rollout highlight where management is focusing its efforts. The combination of AI adoption and an expanding pipeline may influence how the company allocates capital, manages its workforce, and prioritizes obesity and metabolic disease programs in the coming years.
Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.
NYSE:NVO Earnings & Revenue Growth as at May 2026
Quick Assessment
⚖️ Price vs Analyst Target: At $44.39, the stock sits about 8% below the $48.28 analyst price target, suggesting it is close to consensus fair value.
✅ Simply Wall St Valuation: Simply Wall St currently views the stock as trading about 52.8% below its estimated fair value, flagging a wide valuation gap.
✅ Recent Momentum: The share price is up 12.6% over the last 30 days, showing positive short term momentum into the AI partnership and Wegovy pill rollout.
There is only one way to know the right time to buy, sell or hold Novo Nordisk. Head to Simply Wall St’s company report for the latest analysis of Novo Nordisk’s Fair Value..
Key Considerations
📊 The OpenAI deal and obesity pipeline progress tie the investment story more tightly to execution in AI supported R&D, manufacturing, and global Wegovy pill adoption.
📊 Watch how the P/E of 10.3, DCF based undervaluation, and 12.6% 30 day gain evolve as new trial readouts, regulatory updates, and AI deployment milestones land.
⚠️ Key flagged risks include a high level of debt, earnings that are forecast to decline by 0.2% a year over the next 3 years, and a dividend that is not well covered by free cash flows.
Dig Deeper
For the full picture including more risks and rewards, check out the complete Novo Nordisk analysis. Alternatively, you can check out the community page for Novo Nordisk to see how other investors believe this latest news will impact the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NVO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com